Daaweynta loogu talagalay daaweynta sarcoma
Ma jiro qof cusub oo kansar ah, ma jiraan macluumaad badan oo ku saabsan sarcoma. Dhab ahaantii, sarcoma waa nooc ka mid ah kansarka oo inta badan ay dadku iska indhatiraan. Kansarka noocaan ah wuxuu ka soo baxaa maqaarka iyo periosteum, waxayna la mid tahay in la ogaado in xaaladdu ay si degdeg ah uga sii darayso, soo bixitaanka daawooyinka sarcoma-bartilmaameedka ah waxay u oggolaan kartaa bukaannada inay neefsadaan, waxay dejin karaan cudurka waqti gaaban, ka dibna ka hortagga xaaladda halista ah ee metastasis, yaraynta khatarta nafta halis gelinaysa bukaanka.
Daawada la beegsaday ee sarcoma
Bevacizumab, pazopanib, sunitinib, iwm. waa dawooyinka sarcoma-bartilmaameedka, laakiin tani kuma habboona bukaan kasta. Shuruuda ayaa ah in la sameeyo baaritaanka hidda-socodka. Haddii beddelka hidda-wadaha uu yahay beddelka KRAS, MEK inhibitors ayaa la isticmaali karaa, haddii ay tahay beddelka PIK3CA, BKM120, mTOR inhibitor, iwm. Haddii ay tahay beddelka EGFR, daawada TIKi waa la isticmaali karaa. Daawooyinka la bartilmaameedsado ayaa wali fikrado leh, laakiin furaha ayaa ah in si sax ah loo ogaado waxa uu yahay isu beddelka hidde-sidaha, kaas oo u baahan caawinta tignoolajiyada isku xigxiga ee jiilka labaad sababtoo ah inta jeer ee isbeddellada hidda-wadaha ee KRAS, PIK3CA, EGFR iyo MET kuma jiraan ilaa 100% . Haddii xaaladuhu oggolaadaan, AVASTIN sidoo kale waxaa loo isticmaali karaa iyadoo lagu darayo daaweynta kemotherabi.
Waa maxay daawooyinka sarcoma-bartilmaameedka?
1.Bevacizumab
Bevacizumab, a human recombinant VEGF antibody, has been shown to have clinical efficacy in combination regimens in rectal cancer and other malignancies. Agulnik et al. Conducted a multi-center prospective, phase II clinical trial to evaluate the safety and effectiveness of the single-agent bevacizumab, including 30 patients with advanced STS, including 23 cases of angiosarcoma and 7 cases of epithelioid hemangioendothelioma. Monotherapy was well tolerated, partial response (PR), 2 cases, stable disease (SD), 15 cases. After two cycles of treatment, the median progression-free survival (PFS) was 12 weeks, and the overall survival (OS) was 52.7 weeks. This test shows that bevacizumab is safe and effective in patients with angiosarcoma and epithelioid hemangioendothelioma.
2.Pazopanib
Pazopanib waa dawada tyrosine kinase inhibitor-ka yar ee afka laga qaato ee afka laga qaato, waana daawada ugu horraysa ee la bartilmaameedsado oo ay ansixisay FDA muddo tobanaan sano ah si loogu daweeyo sarcoma unug jilicsan oo horumarsan (non-liposarcoma). Pazopanib waa xuubka kobaca xididada xididada xididada VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α iyo -β, FGFR-1 iyo -3, cytokine reseptor (Kit), interleukin-2 reseptor A reseptor tyrosine kinase inhibitor in waxay keeni kartaa T cell kinase (Itk), borotiinka gaarka ah ee leukocyte tyrosine kinase (Lck), iyo transmembrane glycoprotein receptor tyrosine kinase (c-Fms). FDA waxay u ogolaatay pazopanib bukaanada qaba sarcoma sare.
3.Sunitinib
Sunitinib is an oral small molecule receptor tyrosine kinase inhibitor with multiple effects of inhibiting buro angiogenesis and anti-tumor cell growth. Targets for the drug to exert anti-cancer effects include: PDGFR-α and -β, VEGFR1, VEGFR2, VEGFR3, FLT-3, CSF-1R, kit and ret. Sunitide has multiple effector pathways, making it a reliable anti-tumor targeted drug for non-GIST sarcomas, with two phase II clinical trials evaluating its safety and effectiveness.
4.Sorafinib
Sorafenib waa dawooyinka afka laga qaato ee multikinase. Waxay si isku mar ah u joojin kartaa noocyo kala duwan oo ah intracellular iyo kinases dusha unugyada, oo ay ku jiraan BRAF kinase, VEGFR-2, VEGFR-3, PDGFR-β, KIT, iyo FMS-sida tyrosine kinase 3 (FLT-3).
5.Cediranib
Sildenib, oo ah fal-celiyaha kobaca endothelial pan-vascular tyrosine kinase inhibitor, Kumar et al. Waxaa la helay iyada oo loo marayo marxaladda labaad ee daraasadda kiliinikada ee ay muujisay waxtarka wanaagsan ee metastatic acinar jilicsan sarcoma, 35% Bukaanku waxay gaareen PR, SD waxay ku dhacday 60% bukaannada, iyo guud ahaan heerka xakamaynta cudurku wuxuu gaadhay 84% toddobaadyada 24.
6. Anlotinib
Anlotinib waa daaweeyayaasha badan ee bartilmaameedsada tyrosine kinase (RTK) inhibitor kaas oo bartilmaameedsada xuubka kobaca xuubka xuubka xuubka (VEGFR1 / 2/3) iyo soo-dhoweeyaha koritaanka fibroblast (FGFR1 / 2 / 3) Bartilmaameedyada sida soo-dhoweeyayaasha koritaanka platelet (PDGFRa) / β), c-Kit, iyo Ret. Sanadihii la soo dhaafay, cilmi baaris lagu sameeyay isticmaalkeeda daaweynta buro-bartilmaameedka ayaa sii socotay.
